Toll-like receptor 4 knockout mice are protected against PMOS-like pathogenesis

Kiara Wiggins1, Zena Del Mundo1, Julio Ayala Angulo1

  • 1Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, CA, United States.

Reproduction (Cambridge, England)
|July 1, 2026
PubMed

Insights

Toll-like receptor 4 (TLR4) plays a key role in polyendocrine metabolic ovarian syndrome (PMOS)-like conditions. Blocking TLR4 in mice reduced PMOS symptoms and improved gut health, suggesting it as a therapeutic target.

Area of Science:

  • Endocrinology
  • Immunology
  • Reproductive Biology

Background:

  • Polycystine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS), is a complex reproductive endocrine disorder.
  • Chronic immune dysfunction is a recognized feature of PMOS, but the underlying immune activation mechanisms are not fully understood.
  • Gut-derived lipopolysaccharide (LPS) may trigger systemic inflammation through Toll-like receptor 4 (TLR4) activation.

Purpose of the Study:

  • To investigate the role of Toll-like receptor 4 (TLR4) in the development of PMOS-like pathology.
  • To examine the impact of TLR4 deficiency on key features of PMOS in a mouse model.

Main Methods:

  • A letrozole (LET)-induced mouse model was used to mimic PMOS-like pathology.
  • Wild-type and TLR4 knockout (TLR4-/-) female mice were treated with LET.
  • Serum LPS, luteinizing hormone (LH) levels, estrous cycling, fertility, gut barrier integrity, and inflammatory markers were assessed.

Main Results:

  • LET-treated wild-type mice exhibited elevated serum LPS and lipopolysaccharide-binding protein (LBP) compared to LET-treated TLR4-/- mice.
  • TLR4 deficiency significantly attenuated PMOS-like features, including elevated LH, anovulation, and metabolic dysfunction.
  • LET-treated TLR4-/- mice maintained estrous cycling and fertility, preserved gut barrier integrity, and showed reduced inflammation.

Conclusions:

  • Toll-like receptor 4 (TLR4) is a significant contributor to multiple aspects of PMOS-like pathology.
  • Targeting TLR4-mediated inflammation presents a potential therapeutic strategy for women diagnosed with PMOS.